Krystal Biotech, Inc.
KRYS
$180.30
-$3.62-1.97%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 67.33% | 74.57% | 1,570.49% | -89.28% | -89.24% |
| Total Depreciation and Amortization | -13.99% | -64.45% | 100.54% | -33.81% | 15.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.96% | 7.33% | 52.51% | -11.87% | 109.61% |
| Change in Net Operating Assets | -131.11% | 154.65% | -628.38% | 124.21% | -174.28% |
| Cash from Operations | -10.22% | 1,512.12% | -126.23% | 319.69% | 65.93% |
| Capital Expenditure | 23.42% | 7.52% | 10.24% | 31.78% | -3.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -149.31% | -82.65% | 26.29% | -197.37% | -219.22% |
| Cash from Investing | -144.05% | -77.38% | 25.51% | -155.71% | -109.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -27.85% | -68.37% | -33.38% | 509.74% | -80.44% |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -27.85% | -68.37% | 0.52% | 304.09% | -80.44% |
| Foreign Exchange rate Adjustments | -307.69% | 184.87% | -280.21% | 233.57% | -1,266.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -203.27% | 313.16% | -2,049.85% | 104.55% | -115.32% |
